Skip to main content
Premium Trial:

Request an Annual Quote

Target Inks Prostate Assay Deal With Eastern Virginia Medical School

NEW YORK, March 21 (GenomeWeb News) - Target Discovery and the Virginia Prostate Center at Eastern Virginia Medical School are partnering to develop clinical assays to distinguish aggressive and non-aggressive prostate cancer, the company said today.

 

Terms of the agreement call for the Eastern Virginia Medical School to provide patient samples and mass spec analysis. Target will provide its mass defect technology and will integrate the biomarkers in its isonostics clinical platform.

 

Financial details were not provided.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.